Beijing Kawin Technology Share-holding Co Ltd (688687) - Total Assets
Based on the latest financial reports, Beijing Kawin Technology Share-holding Co Ltd (688687) holds total assets worth CN¥2.70 Billion CNY (≈ $394.79 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 688687 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Beijing Kawin Technology Share-holding Co Ltd - Total Assets Trend (2008–2025)
This chart illustrates how Beijing Kawin Technology Share-holding Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 688687 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Beijing Kawin Technology Share-holding Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Beijing Kawin Technology Share-holding Co Ltd's total assets of CN¥2.70 Billion consist of 70.0% current assets and 30.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 29.9% |
| Accounts Receivable | CN¥441.37 Million | 15.8% |
| Inventory | CN¥136.01 Million | 4.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥71.48 Million | 2.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Beijing Kawin Technology Share-holding Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beijing Kawin Technology Share-holding C market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Kawin Technology Share-holding Co Ltd's current assets represent 70.0% of total assets in 2025, an increase from 30.9% in 2008.
- Cash Position: Cash and equivalents constituted 29.9% of total assets in 2025, down from 30.9% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 15.8% of total assets.
Beijing Kawin Technology Share-holding Co Ltd Competitors by Total Assets
Key competitors of Beijing Kawin Technology Share-holding Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Beijing Kawin Technology Share-holding Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.01 | 4.33 | 5.52 |
| Quick Ratio | 2.81 | 3.94 | 5.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.25 Billion | CN¥1.36 Billion | CN¥1.30 Billion |
Beijing Kawin Technology Share-holding Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Kawin Technology Share-holding Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.00 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 6.8% |
| Total Assets | CN¥2.79 Billion |
| Market Capitalization | $415.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Kawin Technology Share-holding Co Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing Kawin Technology Share-holding Co Ltd's assets grew by 6.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing Kawin Technology Share-holding Co Ltd (2008–2025)
The table below shows the annual total assets of Beijing Kawin Technology Share-holding Co Ltd from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.79 Billion ≈ $408.72 Million |
+6.79% |
| 2024-12-31 | CN¥2.62 Billion ≈ $382.75 Million |
+6.84% |
| 2023-12-31 | CN¥2.45 Billion ≈ $358.25 Million |
+10.79% |
| 2022-12-31 | CN¥2.21 Billion ≈ $323.35 Million |
+1.47% |
| 2021-12-31 | CN¥2.18 Billion ≈ $318.67 Million |
+85.78% |
| 2020-12-31 | CN¥1.17 Billion ≈ $171.53 Million |
+11.37% |
| 2019-12-31 | CN¥1.05 Billion ≈ $154.02 Million |
+29.21% |
| 2018-12-31 | CN¥814.56 Million ≈ $119.20 Million |
+12.57% |
| 2017-12-31 | CN¥723.61 Million ≈ $105.89 Million |
+4.08% |
| 2015-12-31 | CN¥695.21 Million ≈ $101.73 Million |
+58.28% |
| 2014-12-31 | CN¥439.24 Million ≈ $64.27 Million |
+8.82% |
| 2013-12-31 | CN¥403.63 Million ≈ $59.06 Million |
+28.98% |
| 2012-12-31 | CN¥312.94 Million ≈ $45.79 Million |
+48.97% |
| 2011-12-31 | CN¥210.07 Million ≈ $30.74 Million |
+27.46% |
| 2010-12-31 | CN¥164.82 Million ≈ $24.12 Million |
+136.95% |
| 2009-12-31 | CN¥69.56 Million ≈ $10.18 Million |
+117.36% |
| 2008-12-31 | CN¥32.00 Million ≈ $4.68 Million |
-- |
About Beijing Kawin Technology Share-holding Co Ltd
Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more